mycophenolate mofetil and systemic lupus erythematosus (SLE) Archives

Abstract Number: 2603 • ACR/ARHP Annual Meeting 2017
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2624 • ACR/ARHP Annual Meeting 2017
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 740 • ACR/ARHP Annual Meeting 2016
Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
Maryam Ghaderi-Yeganeh¹, Ann Biehl², Zerai G. Manna³, Alice Fike⁴ and Sarfaraz Hasni³, ¹National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Lack of adherence to treatment recommendations is a serious confounder to assessment of treatment efficacy for systemic lupus erythematosus (SLE). Estimates of nonadherence with…
Abstract Number: 1824 • ACR/ARHP Annual Meeting 2016
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
Abstract Number: 724 • ACR/ARHP Annual Meeting 2015
Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, its efficacy in extra-renal manifestations of…
Abstract Number: 2937 • ACR/ARHP Annual Meeting 2015
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
J. Madison Hyer¹, Bethany Wolf¹, Jim Oates², Gary S. Gilkeson³ and Diane L. Kamen², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Department of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
Abstract Number: 1804 • ACR/ARHP Annual Meeting 2013
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Ananta Subedi¹, Hong Fang² and Michelle Petri², ¹Good Samaritan Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…

Abstracts tagged "mycophenolate mofetil and systemic lupus erythematosus (SLE)"

Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?

A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis

Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment

Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients

Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study

Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis

Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus